Trial Profile
A Dose Escalation Study of Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Jun 2010 To date, 8 patients have been enrolled, according to a poster presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).
- 16 May 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 May 2009 Actual initiation date (May 2009) added as reported by ClinicalTrials.gov.